< 生产厂家价格 >

比沙可啶

比沙可啶用途

Bisacodyl是刺激性泻剂,能直接刺激结肠产生排便活动。

点击显示

比沙可啶名称

[ CAS 号 ]:
603-50-9

[ 中文名 ]:
比沙可啶

[ 英文名 ]:
Bisacodyl

[中文别名 ]:

[英文别名 ]:

LA96A
laco
neolax
zetrax
durolax
laxine
EINECS 210-044-4
MFCD00038039
ivilax
Bicol

比沙可啶生物活性

[ 描述 ]:

Bisacodyl是刺激性泻剂,能直接刺激结肠产生排便活动。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

[参考文献]

[1]. Ikarashi, N., et al., The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol, 2011. 301(5): p. G887-95.

[2]. Saunders, D.R., et al., Effect of bisacodyl on the structure and function of rodent and human intestine. Gastroenterology, 1977. 72(5 Pt 1): p. 849-56.

[3]. Karmeli, F., R. Stalnikowicz, and D. Rachmilewitz, Effect of colchicine and bisacodyl on rat intestinal transit and nitric oxide synthase activity. Scand J Gastroenterol, 1997. 32(8): p. 791-6.

[4]. Rachmilewitz, D., F. Karmeli, and E. Okon, Effects of bisacodyl on cAMP and prostaglandin E2 contents, (Na + K) ATPase, adenyl cyclase, and phosphodiesterase activities of rat intestine. Dig Dis Sci, 1980. 25(8): p. 602-8.

[5]. Borrelli, F., et al., Effect of bisacodyl and cascara on growth of aberrant crypt foci and malignant tumors in the rat colon. Life Sci, 2001. 69(16): p. 1871-7.

[相关活性小分子]

比沙可啶物理化学性质

[ 密度 ]:
1.2 g/cm3

[ 沸点 ]:
492ºC

[ 熔点 ]:
131 - 135ºC

[ 分子式 ]:
C₂₂H₁₉NO₄

[ 分子量 ]:
361.39100

[ 精确质量 ]:
361.13100

[ PSA ]:
65.49000

[ LogP ]:
4.11240

[ 外观性状 ]:
白色至灰白色结晶粉末

[ 储存条件 ]:
2-8°C

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

比沙可啶MSDS

详细MSDS(安全技术说明书)

比沙可啶毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SM8750000

CHEMICAL NAME :: Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate (ester)

CAS REGISTRY NUMBER :: 603-50-9

BEILSTEIN REFERENCE NO. :: 0323727

LAST UPDATED :: 199701

DATA ITEMS CITED :: 11

MOLECULAR FORMULA :: C22-H19-N-O4

MOLECULAR WEIGHT :: 361.42

WISWESSER LINE NOTATION :: T6NJ BYR DOV1&R DOV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4320 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - other changes Blood - changes in spleen

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 17500 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory stimulation Blood - hemorrhage

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 80 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 2,243,1960

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >15 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,854,1990

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 40 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 40 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 40 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 3,19,1953 *** REVIEWS *** TOXICOLOGY REVIEW DAPOAG Deutsche Apotheker. (Postfach 1650, 6370 Oberusel/Taunas, Fed. Rep. Ger.) V.1- 1949- Volume(issue)/page/year: 27,151,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1651 No. of Facilities: 86 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 431 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1651 No. of Facilities: 132 (estimated) No. of Industries: 2 No. of Occupations: 8 No. of Employees: 2964 (estimated) No. of Female Employees: 1874 (estimated)

点击显示

比沙可啶安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R22;R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
SM8750000

[ 海关编码 ]:
2942000000

比沙可啶合成路线

详细合成路线

比沙可啶上下游产品

比沙可啶上游产品

比沙可啶下游产品

比沙可啶海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

比沙可啶文献

[Bowel preparation for colonoscopy: comparative study using Boston Bowel Preparation Scale].

Acta Gastroenterol. Latinoam. 42(3) , 186-92, (2012)

Most comparative studies on different preparations for colonic cleanliness use unvalidated scales with terms as "excellent," "good," "fair," and "poor" which lack standardized definitions. The Boston ...

Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.

Int. J. Pharm. 409(1-2) , 9-18, (2011)

κ-Carrageenan is a novel pelletisation aid with high formulation robustness and quick disintegration leading to fast drug release unlike the matrix-like release from non-disintegrating microcrystallin...

Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer.

Gastroenterology 147(4) , 903-24, (2014)

更多文献

比沙可啶相关知识

比沙可啶说明书-比沙可啶肠溶片副作用

2018-12-31 14:54:16

导读：比沙可啶能直接刺激小肠和大肠粘膜内感觉神经末梢，使肠蠕动增加，产生缓泻作用。口服后6～12小时内排出软便，对急、慢性便秘均有效，且优于“果导”片。如用栓剂，1小时后即能生效。适用于慢性便秘的治疗。肛门破裂或痔疮溃疡者忌用。服药时不得咀嚼和压碎，服药前后2小时不得服牛奶或抗酸剂。【药品名称】 ...